Korean J Dermatol.  1995 Jun;33(3):504-509.

Therapeutic Effect of Topical Ciclopiroxolamine on Onychomycosis

Abstract

BACKGROUND: Ciclopiroxole.minsolution or cream is the topical in imycotic agent which has been known to have the ability to penetrate the horny skin and nail keratin.
OBJECTIVES
The purpose of this study was to evaluate the pierapeutic effect of 1% ciclopiroxolamine solution on onychomycosis.
METHODS
1% ciclopiroxolamie solution was applied topically to hentire surface of t,he diseased nail at least twice a day for 12 to 36 weeks according to the verity of nail involvement and degree of improvement in 21 cases of onychomycoses.
RESULTS
1. With only topical application of 1% ciclopiroxolamine solutior, 4 out of 21 cases(67%) showed 25% or more reduction of the affected nail area, and 8 out of 21 cases(38%) showed 50% or more reduction of the affected nail area. 2. There was no significant difference in the degree of improvem of according to the duration of disease. 3. Therapeutic effect was relat.ively high on Candida albicans, while it was relatively low on Aspergillus species. 4. 3 out of 7 cases of mild(up to 30%) involvement showed a 7% or more reduction of the affected nail, while 4 out of 6 cases of severe(60-100%) involvement showed a 25% or less reduction of the affected nail. 5. As side effects during the topical application of 1% ciclopiroxol nr ne solution, periungualer ythema appeared in 3 cases, and a burning sensation in 4 of 21 cases.
CONCLUSION
1% ciclopiroir olaniine solution could be tried as an effctive therapeutic agent on onychomycosis for the patient who would not be tolerable to oral an ifiigal medication for associated systemic diseases or who does not want oral medication.

Keyword

Ciclopiroxolaine; Topical; Onychomycosis

MeSH Terms

Aspergillus
Burns
Candida albicans
Humans
Onychomycosis*
Sensation
Skin
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr